MDACC Study No:2010-0065 ( NCT No: NCT01169636)
Title:Phase I Study of Panobinostat Plus ICE Chemotherapy Followed by A Randomized Phase-II Study of ICE compared with Panobinostat Plus ICE For Patients With Relapsed and refractory Classical Hodgkin Lymphoma
Principal Investigator:Yasuhiro Oki
Treatment Agent:Carboplatin; Etoposide; Ifosfamide; LBH589 "B" (oral) ; Panobinostat
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of the
drugs ifosfamide, carboplatin, and etoposide (a routine chemotherapy called
ICE) and panobinostat can help to control relapsed or refractory Hodgkin's
The safety of this drug combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I/Phase II
Treatment Agents:Carboplatin
LBH589 "B" (oral)
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Novartis
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Yasuhiro Oki
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults